We finally have real weapons against the deadliest common cancer

by Adrienne ErinSeptember 3, 2026

Pancreatic  cancer has long carried the lowest survival rate of any major cancer — today, only about 13% of patients survive five years, compared to roughly 70% across all  cancers diagnosed in wealthier countries. Over four out of five cases aren’t caught until they’ve already spread, at which point five-year survival drops to just 3%. But after decades where survival barely moved, several real breakthroughs are finally changing that picture. 

Key Takeaways

• A real 770-patient international trial (NAPOLI-3) found NALIRIFOX improved median survival to 11.1 months vs 9.2 months with standard chemotherapy, leading to FDA approval in February 2024.
• KRAS, the mutation driving 90-95% of pancreatic cancers, was considered “undruggable” for 40 years until a 2013 discovery revealed a hidden binding pocket on the protein.
• Daraxonrasib, a newer, broader RAS-targeting drug, nearly doubled median survival in a real Phase 3 trial (13.2 vs 6.7 months) in previously treated patients.
• An early-phase personalized mRNA cancer vaccine trial showed promising results in a small group of patients, training the immune system to recognize each patient’s unique tumor.
• Cost remains a major unresolved barrier — these treatments can run into six figures over a course of treatment, raising real questions about access.

Why This Cancer Has Been So Hard to Fight

Pancreatic tumors sit deep inside the body and rarely cause noticeable symptoms until they’ve already spread to other organs — there’s no widely used early screening test, so the disease often builds quietly. On top of that, doctors long struggled to understand why patients’ immune systems barely responded at all. Researchers eventually discovered that pancreatic tumors coat themselves with glycoproteins that mimic  healthy cells, effectively signaling the immune system to stand down. Even when some immune response is triggered, T-cells often still can’t infiltrate the tumor itself. 

Making things harder still, as the cancer grows, it damages surrounding tissue and triggers the body’s wound-healing response, creating a dense wall of scar tissue around the tumor called the desmoplastic stroma. This barrier is denser than what surrounds most other cancers, and it does more than just block treatment physically — tumor cells also produce a highly water-attracting sugar that causes swelling inside the tumor, and since the dense stroma prevents that swelling from expanding outward, it creates internal pressure that squeezes shut the very blood vessels that would need to deliver medicine in the first place.

 Discover the four overlooked factors your prescriptions were never designed to address—and why they may still affect how you feel.

Breakthrough #1: A Smarter Chemotherapy (NALIRIFOX)

Traditional chemotherapy doesn’t distinguish between cancer cells and healthy ones — it affects the whole body, and against a tumor this well-protected, that often means significant side effects without reaching the cancer effectively. NALIRIFOX takes a more targeted approach, using a liposomal (fat-encased) form of the chemotherapy drug irinotecan that can slip past healthy tissue and only release its full effect once inside the tumor. 

A real, large international trial called NAPOLI-3 tested this directly: 770 patients with metastatic pancreatic cancer across 18 countries were randomly assigned to receive either NALIRIFOX or the standard first-line chemotherapy combination. Patients on standard chemotherapy had a median survival of 9.2 months; those on NALIRIFOX reached a median of 11.1 months — a real, statistically significant improvement, and patients also stayed on treatment about six weeks longer on average, giving the drug more time to work. Based on these results, the FDA approved NALIRIFOX for metastatic pancreatic cancer in February 2024.

Breakthrough #2: Cracking the “Undruggable” KRAS Mutation

Roughly 90-95% of pancreatic cancers are driven by a mutation in the KRAS gene, which normally acts like an on/off switch controlling cell growth — in most pancreatic cancers, it gets stuck permanently in the “on” position. For 40 years, KRAS was considered untouchable by drugs, because its protein surface was too smooth for any medication to grip onto.

The turning point came in 2013, when biochemist Kevan Shokat at UC San Francisco found that designing molecules to bind to one specific KRAS mutation (called G12C) forced the protein to shift shape, revealing a small hidden pocket researchers named the “Switch II” pocket. That specific discovery only applied to a small fraction of pancreatic  cancers, but it proved KRAS could be targeted at all — something many researchers had doubted for decades. From there, researchers screened hundreds of compounds to find ones that could exploit this same pocket across a broader range of KRAS mutations, eventually leading to a new class of drugs designed to switch the mutated protein back off entirely.

Breakthrough #3: Daraxonrasib — A Broader-Spectrum RAS Inhibitor

Earlier KRAS-targeting drugs worked only against very specific mutations, losing effectiveness entirely if the  cancer mutated further or developed resistance. Daraxonrasib takes a broader approach, designed to target multiple RAS mutation variants at once, recruiting a helper molecule to lock onto the mutated protein and shut down the growth signal it’s been sending. 

In a real Phase 3 trial (RASolute 302) in patients with previously treated metastatic pancreatic cancer, daraxonrasib nearly doubled median overall survival compared to standard chemotherapy — 13.2 months versus 6.7 months. The drug was also generally well tolerated, with fewer patients discontinuing treatment due to side effects compared to chemotherapy. Because KRAS and related RAS mutations also drive a substantial share of lung, colorectal, ovarian, and other cancers, this same approach may eventually extend well beyond pancreatic cancer specifically.